While Zentalis Pharmaceuticals Inc has overperformed by 12.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZNTL fell by -84.58%, with highs and lows ranging from $9.52 to $1.01, whereas the simple moving average fell by -38.49% in the last 200 days.
On August 12, 2024, Wedbush Upgraded Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) to Neutral. A report published by UBS on June 20, 2024, Downgraded its rating to ‘Neutral’ for ZNTL. Wedbush June 18, 2024d the rating to Underperform on June 18, 2024, and set its price target from $15 to $4. Morgan Stanley June 18, 2024d its ‘Overweight’ rating to ‘Equal-Weight’ for ZNTL, as published in its report on June 18, 2024. Jefferies’s report from June 18, 2024 suggests a price prediction of $6 for ZNTL shares, giving the stock a ‘Hold’ rating. Wedbush also rated the stock as ‘Neutral’.
Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
One of the most important indicators of Zentalis Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -59.45% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.94, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ZNTL is recording 832.15K average volume. On a monthly basis, the volatility of the stock is set at 5.81%, whereas on a weekly basis, it is put at 9.94%, with a gain of 1.34% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.28, showing growth from the present price of $1.51, which can serve as yet another indication of whether ZNTL is worth investing in or should be passed over.
How Do You Analyze Zentalis Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 22.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.55% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ZNTL shares are owned by institutional investors to the tune of 76.55% at present.
